SymBio Pharmaceuticals's quarterly market cap
increased
from Jun. 2025 ($43.86 Mil) to Sep. 2025 ($46.48 Mil) but then
declined
from Sep. 2025 ($46.48 Mil) to Dec. 2025 ($37.89 Mil).
SymBio Pharmaceuticals's annual market cap
declined
from Dec. 2023 ($71.72 Mil) to Dec. 2024 ($55.46 Mil) and
declined
from Dec. 2024 ($55.46 Mil) to Dec. 2025 ($37.89 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. SymBio Pharmaceuticals's Enterprise Value for Today is $34.81 Mil.
SymBio Pharmaceuticals (OTCPK:SYMQY) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, SymBio Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SymBio Pharmaceuticals Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, SymBio Pharmaceuticals's Market Cap distribution charts can be found below:
* The bar in red indicates where SymBio Pharmaceuticals's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
SymBio Pharmaceuticals's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SymBio Pharmaceuticals (SYMQY) has a Market Cap of $40.25 Mil as of Jul. 01, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on SymBio Pharmaceuticals and its competitors. According to the industry distribution chart, SymBio Pharmaceuticals ranks #755 out of 1022 companies in the Drug Manufacturers industry, placing it in the top 73.9%.
Is SymBio Pharmaceuticals' Market Cap too high?
SymBio Pharmaceuticals' current Market Cap is $40.25 Mil. The Drug Manufacturers industry median Market Cap is 210.16. SymBio Pharmaceuticals' value of $40.25 Mil is 80.8% below this industry median. Based on the distribution chart, SymBio Pharmaceuticals ranks #755 out of 1022 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, SymBio Pharmaceuticals has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does SymBio Pharmaceuticals' Market Cap compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, SymBio Pharmaceuticals ranks #755 out of 1022 companies for Market Cap. This places SymBio Pharmaceuticals in the lower half of its industry. The industry median Market Cap is 210.16. SymBio Pharmaceuticals' value of $40.25 Mil is 80.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 210.16, based on 1,022 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SymBio Pharmaceuticals's current Market Cap of $40.25 Mil is 80.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on SymBio Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Market Cap is 210.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SymBio Pharmaceuticals's current Market Cap is $40.25 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SymBio Pharmaceuticals stock overvalued right now?
SymBio Pharmaceuticals (SYMQY) has a current Market Cap of $40.25 Mil. The stock's GF Value™ is $0.50, compared to a current price of $0.56 — trading 11.6% above its estimated fair value. The current Market Cap is $40.25 Mil and 80.8% below the Drug Manufacturers industry median of 210.16. SymBio Pharmaceuticals' overall GF Score™ is 35/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For SymBio Pharmaceuticals (SYMQY), the current Market Cap is $40.25 Mil as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SymBio Pharmaceuticals (SYMQY) Overvalued in 2026?
Based on GuruFocus' analysis, SymBio Pharmaceuticals stock appears to be overvalued.
The current stock price of $0.56 is trading 11.6% above its estimated GF Value™ of $0.50.
Key valuation signals for SYMQY:
Market Cap: $40.25 Mil
GF Value™: $0.50 vs. price of $0.56 (11.6% above fair value)
Industry Position: 80.8% below the Drug Manufacturers median (#755 of 1022)
No single metric tells the full story. See the SYMQY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SymBio Pharmaceuticals Ltd is a biopharmaceutical company engaged in development of new drugs with a primary focus on the treatment of rare diseases, mainly in the areas of oncology, hematology and multiple viral infections, and conduct integrated business activities that encompass search for new drug candidates, development, manufacturing, and sales.
35GF Score
Get the complete analysis for SYMQY
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SYMQY has been successfully added to your 
